Oligomeric α-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson's disease
- PMID: 27780739
- DOI: 10.1016/j.neulet.2016.10.039
Oligomeric α-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson's disease
Abstract
Alpha-synuclein oligomerization plays a key role in the development of Parkinson's disease (PD). Being the most common genetic contributor to PD, glucocerebrosidase 1 (GBA) mutations have been associated with decreased GBA enzymatic activity in PD patients with mutations in the GBA gene (GBA-PD). However, it is unknown whether the activities of other lysosomal hydrolases are being altered in GBA-PD patients and are accompanied by an increase in alpha-synuclein oligomerization. The aim of our study was to estimate GBA enzymatic activity as well as the activities of five other lysosomal hydrolases (galactocerebrosidase, alpha-glucosidase, alpha-galactosidase, sphingomyelinase, alpha-iduronidase) in dried blood spots with assessing plasma oligomeric alpha-synuclein levels in sporadic PD (sPD) patients, in GBA-PD patients and in controls. GBA enzymatic activity and plasma oligomeric alpha-synuclein levels were assessed in sPD patients (N=84), in GBA-PD patients (N=21) and controls (N=62) by LC-MS/MS and ELISA methods accordingly. GBA-PD patients showed lower GBA enzymatic activity compared to controls (p=0.001) and to sPD (p=0.0001). We also found the reduction of GLA enzymatic activity (but not of other lysosomal hydrolases) in GBA-PD (p=0.001). At the same time plasma oligomeric alpha-synuclein levels were increased in GBA-PD group compared to sPD and controls (p=0.002 and p<0.0001, respectively). Our results suggest that the decrease in enzymatic activity of lysosomal hydrolases in GBA mutation carriers may contribute to PD pathogenesis by increasing the level of neurotoxic oligomeric alpha-synuclein species.
Keywords: Alpha-synuclein aggregation; Enzymatic activity; GBA mutations; Parkinson’s disease.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.Brain. 2015 Sep;138(Pt 9):2648-58. doi: 10.1093/brain/awv179. Epub 2015 Jun 27. Brain. 2015. PMID: 26117366 Free PMC article.
-
Glucosylsphingosine Promotes α-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease.J Neurosci. 2017 Oct 4;37(40):9617-9631. doi: 10.1523/JNEUROSCI.1525-17.2017. Epub 2017 Aug 28. J Neurosci. 2017. PMID: 28847804 Free PMC article.
-
Plasma oligomeric alpha-synuclein is associated with glucocerebrosidase activity in Gaucher disease.Mov Disord. 2015 Jun;30(7):989-91. doi: 10.1002/mds.26200. Epub 2015 May 12. Mov Disord. 2015. PMID: 25962734
-
Glucocerebrosidase and Parkinson Disease: Molecular, Clinical, and Therapeutic Implications.Neuroscientist. 2018 Oct;24(5):540-559. doi: 10.1177/1073858417748875. Epub 2018 Feb 4. Neuroscientist. 2018. PMID: 29400127 Review.
-
Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review.Transl Neurodegener. 2021 Jan 15;10(1):4. doi: 10.1186/s40035-020-00226-x. Transl Neurodegener. 2021. PMID: 33446243 Free PMC article. Review.
Cited by
-
Glycosphingolipids and neuroinflammation in Parkinson's disease.Mol Neurodegener. 2020 Oct 17;15(1):59. doi: 10.1186/s13024-020-00408-1. Mol Neurodegener. 2020. PMID: 33069254 Free PMC article. Review.
-
GBA1 Variants and Parkinson's Disease: Paving the Way for Targeted Therapy.J Mov Disord. 2023 Sep;16(3):261-278. doi: 10.14802/jmd.23023. Epub 2023 Jun 12. J Mov Disord. 2023. PMID: 37302978 Free PMC article.
-
Monogenetic Forms of Parkinson's Disease - Bridging the Gap Between Genetics and Biomarkers.Front Aging Neurosci. 2022 Mar 3;14:822949. doi: 10.3389/fnagi.2022.822949. eCollection 2022. Front Aging Neurosci. 2022. PMID: 35317530 Free PMC article. Review.
-
The Involvement of Lactosylceramide in Central Nervous System Inflammation Related to Neurodegenerative Disease.Front Aging Neurosci. 2021 Jul 19;13:691230. doi: 10.3389/fnagi.2021.691230. eCollection 2021. Front Aging Neurosci. 2021. PMID: 34349634 Free PMC article. Review.
-
Potential Binding Sites of Pharmacological Chaperone NCGC00241607 on Mutant β-Glucocerebrosidase and Its Efficacy on Patient-Derived Cell Cultures in Gaucher and Parkinson's Disease.Int J Mol Sci. 2023 May 22;24(10):9105. doi: 10.3390/ijms24109105. Int J Mol Sci. 2023. PMID: 37240451 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
